Synergy Asset Management LLC Sells 10,070 Shares of AbbVie Inc. $ABBV

Synergy Asset Management LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 9.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,679 shares of the company’s stock after selling 10,070 shares during the quarter. AbbVie comprises 2.4% of Synergy Asset Management LLC’s portfolio, making the stock its 12th biggest holding. Synergy Asset Management LLC’s holdings in AbbVie were worth $23,004,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. LongView Wealth Management grew its holdings in AbbVie by 23.1% during the 4th quarter. LongView Wealth Management now owns 7,863 shares of the company’s stock worth $1,730,000 after acquiring an additional 1,474 shares during the last quarter. Parsons Capital Management Inc. RI lifted its position in shares of AbbVie by 2.5% during the fourth quarter. Parsons Capital Management Inc. RI now owns 85,891 shares of the company’s stock worth $19,625,000 after purchasing an additional 2,071 shares in the last quarter. Kathmere Capital Management LLC lifted its position in shares of AbbVie by 8.6% during the fourth quarter. Kathmere Capital Management LLC now owns 4,417 shares of the company’s stock worth $1,009,000 after purchasing an additional 351 shares in the last quarter. Norden Group LLC grew its stake in shares of AbbVie by 2.7% during the fourth quarter. Norden Group LLC now owns 19,397 shares of the company’s stock valued at $4,432,000 after purchasing an additional 501 shares during the last quarter. Finally, Mayflower Financial Advisors LLC increased its holdings in shares of AbbVie by 0.4% in the fourth quarter. Mayflower Financial Advisors LLC now owns 19,176 shares of the company’s stock valued at $4,381,000 after purchasing an additional 78 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Evercore cut their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Morgan Stanley raised their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Stock Up 1.9%

Shares of AbbVie stock opened at $211.12 on Friday. The business has a fifty day simple moving average of $222.06 and a 200 day simple moving average of $224.53. The stock has a market cap of $373.29 billion, a PE ratio of 89.46, a price-to-earnings-growth ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics will present 21 evidence-based e-posters at AMWC 2026, highlighting clinical and real‑world data that support product leadership and could help maintain premium pricing and practitioner demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for JUVÉDERM at AMWC, a marketing/product push that may support volume and pricing for AbbVie’s largest aesthetics franchise. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: Erste Group nudged up its FY2027 EPS forecast for AbbVie (to $16.16), a small analyst lift that signals growing analyst confidence in longer‑term earnings power. Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for AbbVie
• Positive Sentiment: AbbVie’s official partnership with MLB (seasonal marketing/awareness) can broaden brand visibility for patient and provider audiences and is a supportive commercial catalyst. How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Zacks and other outlets note elevated investor attention on AbbVie and publish comparative takes (e.g., vs. Eli Lilly) — increased search/coverage can raise short-term volatility but also liquidity. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: Coverage labeling AbbVie as a candidate in the psychedelics/psychiatry theme (coverage of bretisilocin acquisition) may attract growth‑oriented investors, but clinical risk and long timelines keep impact uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Negative Sentiment: Analyst commentary and valuation pieces point to recent share weakness (declines over the past week/month) and ongoing valuation questions despite multi-year gains, which can cap near‑term upside. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.